Reports
Sale
Lupus Nephritis Treatment Market Size, Share, Trends, Report: By Drug Class: NSAIDs, Corticosteroids, Immunosuppressants, Others; Treatment Type: Medication, Dialysis, Kidney Transplant; By Route of Administration: Oral, Parenteral, Others; By End User; By Distribution Channels; Regional Analysis; Supplier Landscape; 2024-2032
Lupus Nephritis Treatment Market Outlook
The lupus nephritis treatment market size was valued at USD 1.8 billion in 2023, driven by the emphasis on preventing kidney failures. The market is expected to grow at a CAGR of 7.5% during the forecast period of 2024-2032, with the values likely to rise from USD 1.9 billion in 2024 to USD 3.4 billion by 2032.
Lupus Nephritis Treatment: Introduction
Lupus is an autoimmune disease wherein the immune system starts attacking the healthy cells of the body. Lupus nephritis is the specific targeting and damage to the kidneys. Proliferative nephritis is the most severe kind of nephritis that may even cause permanent damage to the kidneys. Lupus nephritis treatment includes the administration of corticosteroids, immunosuppressants, blood pressure medications and diuretics. Dietary changes like reduced sodium intake and lesser consumption of protein are also advised as a part of the treatment.
Lupus Nephritis Treatment Market Analysis
Lupus nephritis treatment has observed significant evolution in recent years. B cells play a pivotal role in the pathogenesis of lupus nephritis. Hence, major areas of action in any medication revolve around either B-cell depletion or anti-B-cell activation. Currently, Rituximab is a commonly used medication for lupus nephritis treatment. Numerous medications are also under clinical trials, which are further expected to fuel the lupus nephritis treatment market growth.
Lupus nephritis may lead to chronic kidney failure diseases and is also associated with high blood pressure. Voclosporin (Lupkynis™) has been found safe and effective in treating the disease. It is a structurally modified calcineurin inhibitor, which acts as an immunosuppressant as well as promotes podocyte stability in the kidney. It also led to continuous improvement in proteinuria (presence of protein urine), which is another major symptom of lupus nephritis.
In June 2023, Kyverna Therapeutics, a United States based cell therapy company, received the FDA approval for KYV-101, designed to treat refractory lupus nephritis. The medication works on a novel anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy which depletes B cells, including autoreactive B cells, present in patients with this autoimmune disease. With the advent of new therapies and latest advancements, the lupus nephritis treatment market demand is expected to rise more in the upcoming years.
Lupus Nephritis Treatment Market Segmentation
Market Breakup by Drug Class
- NSAIDs
- Corticosteroids
- Immunosuppressants
- Others
Market Breakup by Treatment Type
- Medication
- Dialysis
- Kidney Transplant
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Market Breakup by End User
- Hospitals and Clinics
- Research and Academic Laboratories
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Lupus Nephritis Treatment Market Overview
The growing convergence of technology into the medical ecosystem has paved the way for artificial intelligence and machine learning enabled diagnosis. The United States, having a robust medical and technical infrastructure, is anticipated to pioneer the lupus nephritis treatment market share in the forecast period. The researchers from University of Houston have also received a USD 3 million grant to offer rapid and precise diagnosis of the disease.
Europe is another major market for lupus nephritis treatment. With a prominent healthcare scenario for the geriatric population, it is home to several leading research and academic institutions working on offering effective treatment options to a wide set of audiences present in the region.
The Asia Pacific region is expected to witness a rapid surge in the lupus nephritis treatment market value, attributed to high investment in building medical infrastructure. There is also an influx of foreign capital, especially from leading medical companies. Government initiatives to spread relevant awareness are also on the rise. Lupus Awareness Month organized every October in Australia is a prime example. This program is aimed at delivering awareness of disease to offer early diagnosis and improve treatment.
Lupus Nephritis Treatment Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- F. Hoffmann-La Roche Ltd
- AstraZeneca
- Aurinia Pharmaceuticals Inc.
- GlaxoSmithKline plc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Vertice Pharma
- Bayer AG
- Sanofi
- Sumitomo Corporation
- LEO Pharma A/S
- Cipla Inc.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Lupus Nephritis Treatment Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Lupus Nephritis Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Lupus Nephritis Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Lupus Nephritis Epidemiology Forecast (2017-2032)
5.3.1 Germany Lupus Nephritis Epidemiology Forecast (2017-2032)
5.3.2 France Lupus Nephritis Epidemiology Forecast (2017-2032)
5.3.3 Italy Lupus Nephritis Epidemiology Forecast (2017-2032)
5.3.4 Spain Lupus Nephritis Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Lupus Nephritis Epidemiology Forecast (2017-2032)
5.4 Japan Lupus Nephritis Epidemiology Forecast (2017-2032)
6 Lupus Nephritis Treatment Market Overview – 7MM
6.1 Lupus Nephritis Treatment Market Historical Value (2017-2023)
6.2 Lupus Nephritis Treatment Market Forecast Value (2024-2032)
7 Lupus Nephritis Treatment Market Landscape – 7MM
7.1 Amyotrophic Lateral Sclerosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Lupus Nephritis Treatment Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Route of Administration
8 Lupus Nephritis Treatment Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Lupus Nephritis Treatment Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Lupus Nephritis Treatment Market Segmentation – 7MM
11.1 Lupus Nephritis Treatment Market by Drug Class
11.1.1 Market Overview
11.1.2 NSAIDs
11.1.3 Corticosteroids
11.1.4 Immunosuppressants
11.1.5 Others
11.2 Lupus Nephritis Treatment Market by Treatment Type
11.2.1 Market Overview
11.2.2 Medication
11.2.3 Dialysis
11.2.4 Kidney Transplant
11.3 Lupus Nephritis Treatment Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Others
11.4 Lupus Nephritis Treatment Market by End User
11.4.1 Market Overview
11.4.2 Hospitals and Clinics
11.4.3 Research and Academic Laboratories
11.4.4 Others
11.5 Lupus Nephritis Treatment Market by Distribution Channels
11.5.1 Market Overview
11.5.2 Hospital Pharmacy
11.5.3 Retail Pharmacy
11.5.4 Online Pharmacy
11.5.5 Others
11.6 Lupus Nephritis Treatment Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Lupus Nephritis Treatment Market
12.1 Lupus Nephritis Treatment Market Historical Value (2017-2023)
12.2 Lupus Nephritis Treatment Market Forecast Value (2024-2032)
12.3 Lupus Nephritis Treatment Market by Drug Class
12.4 Lupus Nephritis Treatment Market by Treatment Type
13 EU-4 and United Kingdom Lupus Nephritis Treatment Market
13.1 Lupus Nephritis Treatment Market Historical Value (2017-2023)
13.2 Lupus Nephritis Treatment Market Forecast Value (2024-2032)
13.3 Germany Lupus Nephritis Treatment Market Overview
13.3.1 Lupus Nephritis Treatment Market by Drug Class
13.3.2 Lupus Nephritis Treatment Market by Treatment Type
13.4 France Lupus Nephritis Treatment Market Overview
13.4.1 Lupus Nephritis Treatment Market by Drug Class
13.4.2 Lupus Nephritis Treatment Market by Treatment Type
13.5 Italy Lupus Nephritis Treatment Market Overview
13.5.1 Lupus Nephritis Treatment Market by Drug Class
13.5.2 Lupus Nephritis Treatment Market by Treatment Type
13.6 Spain Lupus Nephritis Treatment Market Overview
13.6.1 Lupus Nephritis Treatment Market by Drug Class
13.6.2 Lupus Nephritis Treatment Market by Treatment Type
13.7 United Kingdom Lupus Nephritis Treatment Market Overview
13.7.1 Lupus Nephritis Treatment Market by Drug Class
13.7.2 Lupus Nephritis Treatment Market by Treatment Type
14 Japan Lupus Nephritis Treatment Market
14.1 Lupus Nephritis Treatment Market Historical Value (2017-2023)
14.2 Lupus Nephritis Treatment Market Forecast Value (2024-2032)
14.3 Lupus Nephritis Treatment Market by Drug Class
14.4 Lupus Nephritis Treatment Market by Treatment Type
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnerships and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 F. Hoffmann-La Roche Ltd
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 AstraZeneca
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Aurinia Pharmaceuticals Inc.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 GlaxoSmithKline plc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Bristol-Myers Squibb Company
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Eli Lilly and Company
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Merck & Co., Inc.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Novartis AG
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Pfizer Inc.
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Vertice Pharma
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Bayer AG
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Sanofi
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Sumitomo Corporation
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 LEO Pharma A/S
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Cipla Inc.
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Lupus Nephritis Treatment Market- Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 1.8 billion in 2023, driven by the focus on preventing kidney failures associated with lupus nephritis.
The market is anticipated to grow at a CAGR of 7.5% during the forecast period of 2024-2032, likely to reach a market value of USD 3.4 billion by 2032.
The market demand has observed an upswing with the growing incidence of the condition. Moreover, there is also increased focus on early diagnosis and treatment with the help of government initiatives.
Major market trends revolve around the emergence of new medications and therapies like Voclosporin (Lupkynis™) and KYV-101 to treat the disease. Artificial intelligence and machine learning enabled diagnostic methods are also one of the latest trends.
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. EU-4 is categorised into Germany, France, Italy, and Spain.
The market is divided into NSAIDs, corticosteroids, and immunosuppressants, among others.
Treatment types include medication, dialysis, and kidney transplants.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
Major end users include hospitals, clinics, research and academic labs, among others.
The route of administration can be oral and parenteral, among others.
Key players involved in the market are F. Hoffmann-La Roche Ltd, AstraZeneca, Aurinia Pharmaceuticals Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., Bayer AG, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla Inc., and Vertice Pharma.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER